|Day Low/High||81.22 / 82.00|
|52 Wk Low/High||76.67 / 111.11|
Apart from the Fed, there are other factors that make investors nervous.
Gilead Sciences' (GILD) NASH liver disease pipeline is "very attractive," Gabelli said in an analyst note on Thursday.
The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company is stopping its combined Phase 2/3 clinical study of GS-5745, an investigational anti-MMP9 antibody, among patients with moderately to severely active...
Gabelli analysts say Gilead Sciences (GILD) could be the next possible takeover target by Allergan (AGN), as the company has a 'deep pipeline' of NASH drugs.
Gilead (GILD) stock was climbing Tuesday afternoon after Allergan (AGN) said it would buy Tobira (TBRA).
Shares of Gilead Sciences are surging today. Here's how to trade the stock from here.
Buybacks may alert investors to a great opportunity or worthless paperwork.
Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.
The once-mighty biotech has fallen, but entry opportunities will surface.
Jefferies analysts say Gilead's (GILD) $5 billion debt offering could suggest that the company plans to seek out one or several acquisitions, possibly in the orphan diseases sector.
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $5 billion, in an underwritten, registered public offering, consisting of five tranches: ...
Collectively, the data will give investors a clearer measure of Gilead's internal drug development efforts outside of its core hepatitis C and HIV strengths.
Credit Suisse trimmed its price target on shares of Gilead Sciences (GILD) to $95 in a note on Wednesday.
Gilead is a cheap stock with solid turnaround potential and a healthy dividend.
Gilead Sciences (GILD) CEO John Milligan said on Monday that the company won't rule out a large deal but would prefer a series of smaller ones.
It's been a nasty decline, but if we rally, these three have best charts.
How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?
From Altria to Western Union, these 21 companies have must-own dates over the next week.
Gilead Sciences (GILD) said on Friday that it hired former Roche (RHHBY) executive Rogers Luo as VP and general manager of its Chinese commercial operations.
If and when interest rates go up, this basket of stocks should continue to do well.
In the rising biotech sector, it's hard to find solid growth stocks that are also cheap. But we've done the homework for you.
Piper Jaffray said Gilead Sciences (GILD) could be forced to guide full-year 2016 revenue lower than prior estimates.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced webcasts from three upcoming investor conferences: Citi's 11 th Annual Biotech Conference, the 2016 Wells Fargo Healthcare Conference and the Morgan Stanley Global...
Stocks hold mixed by mid-morning Tuesday after U.S. services activity last month declines more than expected.
Gilead has the financial firepower to do a merger or acquisition, which would benefit its shareholders, Cramer says.
U.S. stocks rose Tuesday, as oil prices added one percent on hopes of a production freeze among the world's biggest oil producers.
Gilead Sciences (GILD) stock was upgraded at Jefferies Tuesday morning to 'buy' from 'hold.'